Patents by Inventor Rob N. De Jong

Rob N. De Jong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibodies binding AXL
    Patent number: 12589150
    Abstract: The present invention relates to anti-AXL antibodies, immunoconjugates, compositions and method of treatment of cancer with such anti-AXL antibodies, immunoconjugates, or compositions.
    Type: Grant
    Filed: February 28, 2023
    Date of Patent: March 31, 2026
    Assignee: GENMAB A/S
    Inventors: Esther Breij, David Satijn, Edward Norbert Van Den Brink, Dennis Verzijl, Rob N. De Jong, Paul Parren, Riemke Van Dijkhuizen Radersma
  • HUMAN ANTIBODIES AGAINST TISSUE FACTOR AND METHODS OF USE THEREOF
    Publication number: 20250340669
    Abstract: Isolated human monoclonal antibodies which bind to human TF and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, and therapeutic and diagnostic methods for using the antibodies.
    Type: Application
    Filed: March 12, 2025
    Publication date: November 6, 2025
    Inventors: Sandra VERPLOEGEN, David P.E. SATIJN, Rene M.A. HOET, Paul PARREN, Jan VAN DE WINKEL, Vibeke Miller BREINHOLT, Eva EHRNROOTH, Ole BAADSGAARD, Tom VINK, Willem Karel BLEEKER, Mischa HOUTKAMP, Maroeska OUDSHOORN, Rob N. DE JONG
  • BINDING AGENTS CAPABLE OF BINDING TO CD27 IN COMBINATION THERAPY
    Publication number: 20250325643
    Abstract: The present invention provides combination therapy using a first binding agent comprising at least one binding region binding to CD27 in combination with a second binding agent comprising a first binding region binding to CD40 and a second binding region binding to CD137 to reduce progression or prevent progression of a tumor or treating cancer.
    Type: Application
    Filed: May 12, 2023
    Publication date: October 23, 2025
    Inventors: Esther C. W. BREIJ, Ugur SAHIN, Isil ALTINTAS, Andreea IOAN, Frank BEURSKENS, Rob N. DE JONG, Janine SCHUURMAN, Pauline Linda DE GOEJE, David SATIJN, Peter BOROSS, Andrea IMLE, Kristina NÜRMBERGER, Alexander MUIK, Friederike GIESEKE
  • ANTIBODIES CAPABLE OF BINDING TO CD27, VARIANTS THEREOF AND USES THEREOF
    Publication number: 20250289899
    Abstract: The present invention relates to antibodies capable of binding to human CD27 and to variants thereof comprising a modified Fc region comprising one or more mutations that enhances the Fc-Fc interaction of the antibody. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
    Type: Application
    Filed: March 3, 2025
    Publication date: September 18, 2025
    Inventors: Andreea Ioan, Frank Beurskens, Rob N. de Jong, Janine Schuurman, Esther C. W. Breij, Isil Altintas, Pauline L. de Goeje, David Satijn, Peter Boross, Ugur Sahin, Friederike Gieseke, Alexander Muik, Kristina Schödel
  • ANTIBODIES CAPABLE OF BINDING TO CD27, VARIANTS THEREOF AND USES THEREOF
    Publication number: 20250289900
    Abstract: The present invention relates to antibodies capable of binding to human CD27 and to variants thereof comprising a modified Fc region comprising one or more mutations that enhances the Fc-Fc interaction of the antibody. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
    Type: Application
    Filed: March 3, 2025
    Publication date: September 18, 2025
    Inventors: Andreea Ioan, Frank Beurskens, Rob N. de Jong, Janine Schuurman, Esther C. W. Breij, Isil Altintas, Pauline L. de Goeje, David Satijn, Peter Boross, Ugur Sahin, Friederike Gieseke, Alexander Muik, Kristina Schödel
  • ANTIBODY VARIANTS AND USES THEREOF
    Publication number: 20250223374
    Abstract: Described herein are polypeptides and related antibodies comprising a variant Fc domain. The variant Fc domain provide for stabilized Fc:Fc interactions when the polypeptide(s), antibody or antibodies are bound to its target, antigen or antigens on the surface of a cell, thus providing for improved effector functions, such as CDC-response.
    Type: Application
    Filed: August 27, 2024
    Publication date: July 10, 2025
    Inventors: Paul PARREN, Frank Beurskens, Rob N. De Jong, Aran Frank Labrijn, Janine Schuurman
  • HUMAN IGG1 FC REGION VARIANTS AND USES THEREOF
    Publication number: 20250145720
    Abstract: Described herein are polypeptides and related antibodies comprising a variant Fc domain. The variant Fc domain provide for stabilized Fc: Fc interactions when the poly-peptide(s), antibody or antibodies are bound to its target, antigen or antigens on the surface of a cell, thus providing for improved complement-dependent cytotoxicity (CDC).
    Type: Application
    Filed: June 14, 2024
    Publication date: May 8, 2025
    Inventors: Paul PARREN, Frank BEURSKENS, Rob N. DE JONG, Sandra VERPLOEGEN, Aran Frank LABRIJN, Janine SCHUURMAN
  • ANTIBODY VARIANTS AND USES THEREOF
    Publication number: 20250043018
    Abstract: Described herein are polypeptides and related antibodies comprising a variant Fc domain. The variant Fc domain provide for stabilized Fc:Fc interactions when the polypeptide(s), antibody or antibodies are bound to its target, antigen or antigens on the surface of a cell, thus providing for improved effector functions, such as CDC-response.
    Type: Application
    Filed: June 12, 2024
    Publication date: February 6, 2025
    Inventors: Paul PARREN, Frank BEURSKENS, Rob N. DE JONG, Aran Frank LABRIJN, Janine SCHUURMAN
  • Antibody variants and uses thereof
    Patent number: 12049512
    Abstract: Described herein are polypeptides and related antibodies comprising a variant Fc domain. The variant Fc domain provide for stabilized Fc:Fc interactions when the polypeptide(s), antibody or antibodies are bound to its target, antigen or antigens on the surface of a cell, thus providing for improved effector functions, such as CDC-response.
    Type: Grant
    Filed: July 6, 2020
    Date of Patent: July 30, 2024
    Assignee: GENMAB B.V.
    Inventors: Paul Parren, Frank Beurskens, Rob N. De Jong, Aran Frank Labrijn, Janine Schuurman
  • ANTIBODIES BINDING AXL
    Publication number: 20240091352
    Abstract: The present invention relates to anti-AXL antibodies, immunoconjugates, compositions and method of treatment of cancer with such anti-AXL antibodies, immunoconjugates, or compositions.
    Type: Application
    Filed: February 28, 2023
    Publication date: March 21, 2024
    Inventors: Esther BREIJ, David SATIJN, Edward Norbert VAN DEN BRINK, Dennis VERZIJL, Rob N. DE JONG, Paul PARREN, Riemke VAN DIJKHUIZEN RADERSMA
  • HUMAN ANTIBODIES AGAINST TISSUE FACTOR AND METHODS OF USE THEREOF
    Publication number: 20230416403
    Abstract: Isolated human monoclonal antibodies which bind to human TF and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, and therapeutic and diagnostic methods for using the antibodies.
    Type: Application
    Filed: December 6, 2022
    Publication date: December 28, 2023
    Inventors: Sandra VERPLOEGEN, David P. E. SATIJN, Rene M. A. HOET, Paul PARREN, Jan VAN DE WINKEL, Vibeke Miller BREINHOLT, Eva EHRNROOTH, Ole BAADSGAARD, Tom VINK, Willem Karel BLEEKER, Mischa HOUTKAMP, Maroeska OUDSHOORN, Rob N. DE JONG
  • ANTIBODIES CAPABLE OF BINDING TO CD27, VARIANTS THEREOF AND USES THEREOF
    Publication number: 20230212301
    Abstract: The present invention relates to antibodies capable of binding to human CD27 and to variants thereof comprising a modified Fc region comprising one or more mutations that enhances the Fc-Fc interaction of the antibody. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
    Type: Application
    Filed: November 14, 2022
    Publication date: July 6, 2023
    Inventors: Andreea Ioan, Frank Beurskens, Rob N. de Jong, Janine Schuurman, Esther C. W. Breij, Isil Altintas, Pauline L. de Goeje, David Satijn, Peter Boross, Ugur Sahin, Friederike Gieseke, Alexander Muik, Kristina Schödel
  • ANTIBODIES CAPABLE OF BINDING TO CD27, VARIANTS THEREOF AND USES THEREOF
    Publication number: 20230109496
    Abstract: The present invention relates to antibodies capable of binding to human CD27 and to variants thereof comprising a modified Fc region comprising one or more mutations that enhances the Fc-Fc interaction of the antibody. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
    Type: Application
    Filed: September 6, 2022
    Publication date: April 6, 2023
    Inventors: Andreea Ioan, Frank Beurskens, Rob N. de Jong, Janine Schuurman, Esther C. W. Breij, Isil Altintas, Pauline L. de Goeje, David Satijn, Peter Boross, Ugur Sahin, Friederike Gieseke, Alexander Muik, Kristina Schödel
  • METHODS FOR THE QUANTIFICATION OF GLYCOPROTEINS
    Publication number: 20230089196
    Abstract: The invention relates to methods for the quantification of glycoproteins in a sample, comprising quantifying said glycoproteins by comparison with an internal standard, wherein said internal standard comprises variant forms of said glycoproteins, wherein said variant forms contain only core Asn-linked GlcNAc moieties.
    Type: Application
    Filed: February 19, 2021
    Publication date: March 23, 2023
    Inventors: Ewald T.J. VAN DEN BREMER, Sipke SANGERS, Demelza WILLEMSZ, Richard G. HIBBERT, Rob N. DE JONG, Søren Skov JENSEN, Emil POULSEN
  • Dimeric protein with triple mutations
    Patent number: 11180572
    Abstract: The present invention relates to dimeric proteins comprising amino acids at three different positions which are different from those present in a human IgG1. Six of said dimeric proteins are capable of forming a hexameric structure in solution.
    Type: Grant
    Filed: July 5, 2013
    Date of Patent: November 23, 2021
    Assignee: GENMAB B.V.
    Inventors: Rob N. De Jong, Frank Beurskens, Paul Parren, Aran Frank Labrijn, Janine Schuurman, Arjen Vlug, Sandra Verploegen
  • DIMERIC PROTEIN WITH TRIPLE MUTATIONS
    Publication number: 20210230301
    Abstract: The present invention relates to dimeric proteins comprising amino acids at three different positions which are different from those present in a human IgG1. Six of said dimeric proteins are capable of forming a hexameric structure in solution.
    Type: Application
    Filed: September 4, 2020
    Publication date: July 29, 2021
    Inventors: Rob N. DE JONG, Frank BEURSKENS, Paul PARREN, Aran Frank LABRIJN, Janine SCHUURMAN, Arjen VLUG, Sandra VERPLOEGEN
  • HUMAN ANTIBODIES AGAINST TISSUE FACTOR AND METHODS OF USE THEREOF
    Publication number: 20210171657
    Abstract: Isolated human monoclonal antibodies which bind to human TF and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, and therapeutic and diagnostic methods for using the antibodies.
    Type: Application
    Filed: May 21, 2020
    Publication date: June 10, 2021
    Applicants: GENMAB A/S, GENMAB A/S
    Inventors: Sandra VERPLOEGEN, David P.E. SATIJN, Rene M.A. HOET, Paul PARREN, Jan VAN DE WINKEL, Vibeke Miller BREINHOLT, Eva EHRNROOTH, Ole BAADSGAARD, D.M.Sc., Tom VINK, Willem Karel BLEEKER, Mischa HOUTKAMP, Maroeska OUDSHOORN, Rob N. DE JONG
  • ANTIBODY VARIANTS AND USES THEREOF
    Publication number: 20210163619
    Abstract: Described herein are polypeptides and related antibodies comprising a variant Fc domain. The variant Fc domain provide for stabilized Fc:Fc interactions when the polypeptide(s), antibody or antibodies are bound to its target, antigen or antigens on the surface of a cell, thus providing for improved effector functions, such as CDC-response.
    Type: Application
    Filed: July 6, 2020
    Publication date: June 3, 2021
    Inventors: Paul PARREN, Frank BEURSKENS, Rob N. DE JONG, Aran Frank LABRIJN, Janine SCHUURMAN
  • Antibodies binding AXL
    Patent number: 10765743
    Abstract: The present invention relates to anti-AXL antibodies, immunoconjugates, compositions and method of treatment of cancer with such anti-AXL antibodies, immunoconjugates, or compositions.
    Type: Grant
    Filed: January 15, 2019
    Date of Patent: September 8, 2020
    Assignee: GENMAB A/S
    Inventors: Esther Breij, David Satijn, Edward Norbert Van Den Brink, Dennis Verzijl, Rob N. De Jong, Paul Parren, Riemke Van Dijkhuizen Radersma
  • Antibody variants and uses thereof
    Patent number: 10759867
    Abstract: Described herein are polypeptides and related antibodies comprising a variant Fc domain. The variant Fc domain provide for stabilized Fc:Fc interactions when the polypeptide(s), antibody or antibodies are bound to its target, antigen or antigens on the surface of a cell, thus providing for improved effector functions, such as CDC-response.
    Type: Grant
    Filed: July 6, 2012
    Date of Patent: September 1, 2020
    Assignee: GENMAB B.V.
    Inventors: Paul Parren, Frank Beurskens, Rob N. De Jong, Aran Frank Labrijn, Janine Schuurman